Bile duct inflammation and scarring, known as cholangiopathies, can disrupt bile flow, leading to liver damage and ...

The results of a clinical trial led by researchers at the University of Arizona Health Sciences and published in the Journal of Clinical Oncology show that chemotherapy combining three different ...

Background: The presence of infective microorganisms in the bilio-pancreatic tract is believed to be important in both the onset and outcome of acute biliary pancreatitis. In this study ...

They are rare cancers with few treatment options and low survival rates. But new molecular testing, available in Ottawa and ...

Circulating tumor DNA may be a prognostic biomarker for relapse and early recurrence detection in resected early-stage biliary tract cancer. Among patients with curatively resected early-stage biliary ...

Eisai has filed for approval in Japan for tasurgratinib, its small-molecule fibroblast growth factor (FGF) receptor inhibitor, as a treatment for biliary tract cancers with FGFR2 gene fusion ...

Ceramide metabolism has garnered increasing attention in liver diseases, but its role in cholestatic liver injury remains unclear. Here the authors show that targeting ACER3, a ceramidase ...

Galbraith continued, “Turning to our most advanced partnered product, Ziihera ® (zanidatamab-hrii) achieved a major milestone with its accelerated approval and launch for HER2-positive biliary tract ...

Despite posting disappointing top revenue and earnings misses for Q4 last week, Zymeworks (ZYME) has seen its shares rally over 5%, thanks in ...

Eisai has launched its new therapy for biliary tract cancer (BTC) Tasfygo in Japan, the first world market for the drug. Tasfygo (tasurgratinib succinate; formerly E7090), a small-molecule ...